Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2017

01-07-2017 | Breast Oncology

The Impact of Reexcision and Residual Disease on Local Recurrence Following Breast-Conserving Therapy

Authors: Stephen A. Mihalcik, MD, PhD, Bhupendra Rawal, MS, Lior Z. Braunstein, MD, Alex Capuco, BA, Julia S. Wong, MD, Rinaa S. Punglia, MD, MPH, Jennifer R. Bellon, MD, Jay R. Harris, MD

Published in: Annals of Surgical Oncology | Issue 7/2017

Login to get access

Abstract

Purpose

Risk factors for local recurrence (LR) following breast-conserving therapy (BCT) inform the need for local therapy. A Danish population-based cohort study identified residual disease on reexcision as an independent risk factor for LR but was limited by incomplete data on biologic subtype (Bodilsen et al. 2015 in Ann Surg Oncol 22: S476–S485). We sought to elaborate this risk in an independent cohort with clearly defined biologic subtypes.

Methods

The study population included patients with localized invasive breast cancer with complete biologic subtype data treated with BCT with one or zero reexcisions at one institution from 1998 to 2008. Cumulative incidence of LR was calculated using competing risk analysis, and associated risk factors were evaluated using Cox proportional hazards regression.

Results

A total 1073 consecutive patients were included with a median follow-up of 10 years. The 10-year LR rates were 2.4% [95% confidence interval (CI) 1.4–3.9%] without reexcision, 6.0% (95% CI 3.8–8.9%) with reexcision, and 8.2% (95% CI 4.1–14.0%) with any reexcised residual disease. On univariate regression, residual disease [hazard ratio (HR) = 1.50, p = 0.31] was not significantly associated with LR. Subtype other than luminal A/luminal-HER2 (luminal B HR = 2.29, p = 0.033; HER2/triple-negative HR = 2.85, p = 0.004), age (HR = 0.95 per year, p < 0.001), and nodal involvement (HR = 1.12 per involved node, p = 0.001) remained significant on multivariate regression. The impact of residual disease was confounded by its association (p < 0.001) with nodal involvement.

Conclusions

Our findings suggest that LR is associated with younger age, nodal involvement, and biologic subtype but not with residual disease at reexcision. The study’s power is limited by the low incidence of LR despite detailed clinical data and long-term follow-up. Further study is required.
Literature
1.
Bodilsen A, Bjerre K, Offersen BV, et al. The influence of repeat surgery and residual disease on recurrence after breast-conserving surgery: a Danish Breast Cancer Cooperative Group Study. Ann Surg Oncol. 2015;22 Suppl 3:S476–85.CrossRefPubMed
2.
Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106.CrossRefPubMed
3.
Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41.CrossRefPubMed
4.
Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–32.CrossRefPubMed
5.
Aziz D, Rawlinson E, Narod SA, et al. The role of reexcision for positive margins in optimizing local disease control after breast-conserving surgery for cancer. Breast J. 2006;12(4):331–7.CrossRefPubMed
6.
Kotwall C, Ranson M, Stiles A, Hamann MS. Relationship between initial margin status for invasive breast cancer and residual carcinoma after re-excision. Am Surg. 2007;73(4):337–43.PubMed
7.
McCahill LE, Single RM, Aiello Bowles EJ, et al. Variability in reexcision following breast conservation surgery. JAMA. 2012;307(5):467–75.CrossRefPubMed
8.
9.
Waljee JF, Hu ES, Newman LA, Alderman AK. Predictors of re-excision among women undergoing breast-conserving surgery for cancer. Ann Surg Oncol. 2008;15(5):1297–303.CrossRefPubMed
10.
Buchholz TA, Somerfield MR, Griggs JJ, et al. Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. J Clin Oncol. 2014;32(14):1502–6.CrossRefPubMed
11.
Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Ann Surg Oncol. 2014;21(3):704–16.CrossRefPubMed
12.
Adams BJ, Zoon CK, Stevenson C, Chitnavis P, Wolfe L, Bear HD. The role of margin status and reexcision in local recurrence following breast conservation surgery. Ann Surg Oncol. 2013;20(7):2250–5.CrossRefPubMed
13.
Menes TS, Tartter PI, Bleiweiss I, Godbold JH, Estabrook A, Smith SR. The consequence of multiple re-excisions to obtain clear lumpectomy margins in breast cancer patients. Ann Surg Oncol. 2005;12(11):881–5.CrossRefPubMed
14.
O’Sullivan MJ, Li T, Freedman G, Morrow M. The effect of multiple reexcisions on the risk of local recurrence after breast conserving surgery. Ann Surg Oncol. 2007;14(11):3133–40.CrossRefPubMed
15.
Ali AN, Vapiwala N, Guo M, Hwang WT, Harris EE, Solin LJ. The impact of re-excision and residual disease on local recurrence after breast conservation treatment for patients with early stage breast cancer. Clin Breast Cancer. 2011;11(6):400–5.CrossRefPubMed
16.
Kouzminova NB, Aggarwal S, Aggarwal A, Allo MD, Lin AY. Impact of initial surgical margins and residual cancer upon re-excision on outcome of patients with localized breast cancer. Am J Surg. 2009;198(6):771–80.CrossRefPubMed
17.
Hattangadi-Gluth JA, Wo JY, Nguyen PL, et al. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2012;82(3):1185–91.CrossRefPubMed
18.
Russo AL, Arvold ND, Niemierko A, et al. Margin status and the risk of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy. Breast Cancer Res Treat. 2013;140(2):353–61.CrossRefPubMed
19.
Tseng YD, Uno H, Hughes ME, et al. Biological subtype predicts risk of locoregional recurrence after mastectomy and impact of postmastectomy radiation in a large national database. Int J Radiat Oncol Biol Phys. 2015;93(3):622–30.CrossRefPubMed
20.
Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 2011;29(29):3885–91.CrossRefPubMedPubMedCentral
21.
Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009;27(34):5700–6.CrossRefPubMedPubMedCentral
22.
Albert JM, Gonzalez-Angulo AM, Guray M, et al. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys. 2010;77(5):1296–302.CrossRefPubMed
23.
Caudle AS, Yu TK, Tucker SL, et al. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res. 2012;14(3):R83.CrossRefPubMedPubMedCentral
24.
Swisher SK, Vila J, Tucker SL, et al. Locoregional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast-conserving therapy. Ann Surg Oncol. 2016;23(3):749–56.CrossRefPubMed
25.
Chism DB, Freedman GM, Li T, Anderson PR. Re-excision of margins before breast radiation-diagnostic or therapeutic? Int J Radiat Oncol Biol Phys. 2006;65(5):1416–21.CrossRefPubMed
26.
Halevy A, Lavy R, Pappo I, et al. Indication for relumpectomy—a useful scoring system in cases of invasive breast cancer. J Surg Oncol. 2012;105(4):376–80.CrossRefPubMed
27.
Jaffre I, Campion L, Dejode M, et al. Margin width should not still enforce a systematic surgical re-excision in the conservative treatment of early breast infiltrative ductal carcinoma. Ann Surg Oncol. 2013;20(12):3831–8.CrossRefPubMed
28.
Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–502.CrossRefPubMed
29.
Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.CrossRefPubMed
30.
Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74.CrossRefPubMedPubMedCentral
Metadata
Title
The Impact of Reexcision and Residual Disease on Local Recurrence Following Breast-Conserving Therapy
Authors
Stephen A. Mihalcik, MD, PhD
Bhupendra Rawal, MS
Lior Z. Braunstein, MD
Alex Capuco, BA
Julia S. Wong, MD
Rinaa S. Punglia, MD, MPH
Jennifer R. Bellon, MD
Jay R. Harris, MD
Publication date
01-07-2017
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 7/2017
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5727-9

Other articles of this Issue 7/2017

Annals of Surgical Oncology 7/2017 Go to the issue

Gynecologic Oncology

A Prospective Cohort Study Comparing Colorimetric and Fluorescent Imaging for Sentinel Lymph Node Mapping in Endometrial Cancer

Colorectal Cancer

Nonoperative Management or ‘Watch and Wait’ for Rectal Cancer with Complete Clinical Response After Neoadjuvant Chemoradiotherapy: A Critical Appraisal

Breast Oncology

Opportunistic Biopsy of Internal Mammary Lymph Nodes During Immediate Breast Reconstruction After Mastectomy for Breast Malignancies

Hepatobiliary Tumors

Expansion of Criteria for Liver Transplantation in Hepatocellular Carcinoma: Better Patient Selection or a Slippery Slope?

Colorectal Cancer

Three Different Approaches to the Inferior Mesenteric Artery during Robotic D3 Lymphadenectomy for Rectal Cancer

Hepatobiliary Tumors

Liver Transplantation is a Preferable Alternative to Palliative Therapy for Selected Patients with Advanced Hepatocellular Carcinoma